NVO
Novo Nordisk A/S · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -10.6% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 485.23K | $18.43M | n/a | n/a |
| Q2 2026 | 134 | +1 | 236.29M | $11.33B | +13 | −12 |
| Q1 2026 | 134 | -8 | 242.80M | $8.91B | +5 | −13 |
| Q4 2025 | 140 | +1 | 228.46M | $11.63B | +3 | −2 |
| Q3 2025 | 19 | -1 | 80.89M | $4.49B | +2 | −3 |
| Q2 2025 | 17 | -1 | 53.30M | $3.68B | +1 | −2 |
| Q1 2025 | 16 | 0 | 43.10M | $3.00B | n/a | n/a |
| Q4 2024 | 16 | -1 | 48.20M | $4.15B | +1 | −2 |
| Q3 2024 | 16 | -1 | 43.13M | $5.09B | +1 | −2 |
| Q2 2024 | 17 | n/a | 46.04M | $6.57B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fisher Asset Management ✦ | 11.87M | -6.1% | $824.34M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 6.82M | -17.9% | $473.68M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 6.00M | -0.9% | $422.47M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 5.32M | -16.1% | $369.75M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 3.15M | +70.7% | $218.59M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 2.58M | +25.7% | $179.33M | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Markel Group ✦ | 2.15M | 0.0% | $149.30M | 1.3% | Held | 4 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 1.72M | +172.3% | $119.33M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 9 | Tiger Global Management ✦ | 1.27M | 0.0% | $88.12M | 0.3% | Held | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.02M | +23.0% | $70.95M | 0.0% | ▲ Add | 3 | SEC ↗ ×6 |
| 11 | Millennium Management ✦ | 887.69K | +149.9% | $61.64M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 12 | Capital World Investors ✦ | 207.77K | -95.3% | $14.40M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 62.10K | +20.9% | $4.31M | 0.0% | ▲ Add | 4 | SEC ↗ ×3 |
| 14 | Marshall Wace ✦ | 25.12K | -97.8% | $1.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 10.74K | -77.8% | $745,647 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Baillie Gifford ✦ | 176 | +232.1% | $12,221 | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1.21M shares, $43.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.